- NetraMark's AI platform, NetraAI, outperformed ChatGPT, DeepSeek, and traditional machine learning in clinical trial data analysis.
- NetraAI achieved accuracy rates of 85-100% across various trials, identifying patient subgroups using only 2-4 variables.
- The platform's capabilities could significantly reduce clinical trial failures and improve drug development success rates.
NetraMark Holdings Inc. (CSE: AIAI, OTCQB: AINMF, Frankfurt: PF0) has unveiled a groundbreaking study showcasing that its AI platform, NetraAI, significantly surpasses ChatGPT, DeepSeek, and traditional machine learning techniques in analyzing clinical trial data. The study demonstrated NetraAI's potential using complex datasets from three different trials: CATIE (schizophrenia), CAN-BIND (depression), and COMPASS (pancreatic cancer).
NetraAI's performance was remarkable, showing accuracy rates between 85% and 100%, while effectively identifying clinically meaningful patient subgroups with just 2-4 clinical variables. This achievement contrasts sharply with the results of ChatGPT and DeepSeek, which were unable to generate statistically valid insights from the same datasets.
The superiority of NetraAI is attributed to its unique mathematical foundation, which combines dynamical systems theory and evolutionary computation. This allows the platform to optimize clinical trials and stratify patients more effectively. Notably, NetraAI's ability to identify specific patient subgroups and provide interpretable results is poised to lower trial failure rates and enhance drug development success.
In trials involving schizophrenia, depression, and pancreatic cancer, NetraAI not only provided statistically significant insights but also delivered clear and actionable outcomes that could be utilized for regulatory submissions. The study underscores a shift from traditional AI tools to more specialized, precision-built AI systems in the field of medicine.
